New perspectives in the management of pancreas cancer

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 11, 2003, Pages 3-10

  Haller, Daniel G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; CYTOTOXIC AGENT; DOCETAXEL; EXATECAN; FLUOROURACIL; FOLIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PEMETREXED; RUBITECAN; TIPIFARNIB;

ADVANCED CANCER; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DIAGNOSTIC TEST; DIARRHEA; DRUG EFFICACY; HEALTH CARE QUALITY; HUMAN; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PANCREAS CANCER; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 0041335589     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00296-3     Document Type: Conference Paper

References (41)

1. Evans DB, Abbruzzese JL, Willett CG: Cancer of the pancreas, in Devita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 6; vol 1). Philadelphia, PA, Lippincott, Williams and Wilkins, 1997, pp 1126-1161
2. American Cancer Society: Cancer Facts and Figures. American Cancer Society, Atlanta, GA, 2003
3. Haller DR: Chemotherapy for advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 56:16-23, 2003 (suppl 4)
4. Warshaw AL, Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 326:455-465, 1992
5. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
6. Mallinson CN, Rake MO, Cocking JB, et al: Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomised, multicentre trial. Br Med J 281:1589-1591, 1980
7. Cullinan S, Moertel CG, Wieand HS, et al: A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65:2207-2212, 1990
8. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29-34, 1994
9. Moore MJ, Hamm J, Eisenberg P, et al: A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (pts) with advanced pancreatic cancer. Proc Am Soc Clin Oncol 19:240a, 2000 (abstr 930)
10. Bramhall SR, Rosemurgy A, Brown PD, et al: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J Clin Oncol 19:3447-3455, 2001
11. Bramhall SR, Schulz J, Nemunaitis J, et al: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161-167, 2002
12. Colucci G, Giuliani F, Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94:902-910, 2002
13. Berlin JD, Catalano P, Thomas JP, et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275, 2002
14. Van Cutsem E, Karasek P, Oettle H, et al: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 21:130a, 2002 (abstr 517)
15. Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347-353, 1996
16. Storniolo AM, Enas NH, Brown CA, et al: An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma. Cancer 85:1261-1268, 1999
17. Grunewald R, Abbruzzese JL, Tarassoff P, et al: Saturation of 2′2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258-262, 1991
18. Tempero M, Plunkett W, Ruiz van Haperen V, et al: Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 18:273a, 1999 (abstr 1048)
19. Pastorelli D, Pedrazzoli S, Sperti C, et al: Phase II trial with gemcitabine (GEM) + 5-fluorouracil (5-FU) in advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 19:284a, 2000 (abstr 1110)
20. Cascinu S, Silva RR, Barni S, et al: A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 80:1595-1598, 1999
21. Hidalgo M, Castellano D, Paz-Ares L: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17:585-592, 1999
22. Rodríguez-Lescure A, Carrato A, Massuti B, et al: Phase I-II study of gemcitabine (GEM) and weekly 48-hour continuous infusion (CI) of high dose 5-fluorouracil (5-FU) in advanced exocrine pancreatic cancer (APC). Proc Am Soc Clin Oncol 18:298a, 1999 (abstr 1145)
23. Anchisi S, Delaloye B, Petite J, et al: Gemcitabine (Gem) and continuous infusional 5-FU (Cif) is active and well tolerated in advanced or metastatic pancreatic cancer. Proc Am Soc Clin Oncol 19:326a, 2000 (abstr 1280H)
24. Riedel C, Wein A, Wehler M, et al: High-dose 5-fluorouracil (FU) 24-H-infusion with gemcitabine (GEM): Tolerable and efficient in palliative outpatient treatment of pancreatic cancer. Proc Am Soc Clin Oncol 19:316a, 2000 (abstr 1248)
25. Rauch DP, Maurer CA, Aebi S, et al: Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology 60:43-48, 2001
26. Louvet C, Hammel P, André T, et al: Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5FU bolus and infusion, and gemcitabine (FOLFUGEM regimen). Proc Am Soc Clin Oncol 18:275a, 1999 (abstr 1054)
27. Polyzos A, Tsavaris N, Kosmas C, et al: A phase II study of gemcitabine (GEM) plus 5-fluorouracil (5-FU) modulated by leucovorin (LV) for advanced pancreatic cancer. Proc Am Soc Clin Oncol 19:311a, 2000 (abstr 1229)
28. Gemzar (gemcitabine HCl) package insert. Indianapolis, IN, Eli Lilly and Company. Updated August 1998
29. Heinemann V, Wilke H, Possinger K, et al: Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer. Final results of a phase II study. Proc Am Soc Clin Oncol 18:274a, 1999 (abstr 1053)
30. Philip PA, Zalupski M, Vaitkevicius VK, et al: Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer. Proc Am Soc Clin Oncol 18:274a, 1999 (abstr 1053)
31. Colucci G, Riccardi F, Giuliani F, et al: Randomized trial of gemcitabine (GEM) alone or with cisplatin (CDDP) in the treatment of advanced pancreatic cancer (APC): A phase II multicenter study of the Southern Italy Oncology Group. Proc Am Soc Clin Oncol 18:250a, 1999 (abstr 961)
32. Wagener DJ, Verdonk HE, Dirix LY, et al: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 6:129-132, 1995
33. CPT-11 Study Group on Gastrointestinal Cancer, Sakata Y, Shimada Y, Yoshino M, et al: A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. Gan To Kagaku Ryoho 21:1039-1046, 1994
34. Rocha Lima C, Savarese D, Bruckner H, et al: Multicenter phase II trial of first-line irinotecan and gemcitabine (irinogem) in patients with locally advanced or metastatic pancreatic cancer (PC). Proc Am Soc Clin Oncol 19:263a 2000 (abstr 1023)
35. Stathopoulos G, Rigatos G, Dimopoulos M, et al: Front-line treatment of pancreatic carcinoma with gemcitabine (GMB) in combination with irinotecan (CPT-11): Preliminary results of a multicenter phase II study. Proc Am Soc Clin Oncol 19:319a, 2000 (abstr 1260)
36. Jacobs AD, Otero H, Picozzi V Jr, et al: A phase I/II study of gemcitabine (G) and docetaxel (D) in patients (pts) with unresectable pancreatic cancer. Proc Am Soc Clin Oncol 19:265a, 2000 (abstr 1032)
37. Louvet C, Andre T, Lledo P, et al: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study. J Clin Oncol 20:1512-1518, 2002
38. Mendelsohn LG, Shih C, Chen VJ, et al: Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 26:42-47, 1999 (suppl 6)
39. Miller KD, Picus J, Blanke C, et al: Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 11:101-103, 2000
40. Kindler HL, Dugan W, Hochster H, et al: Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine. Proc Am Soc Clin Oncol 21:125a, 2002 (abstr 499)
41. Lawrence TS, Eisbruch A, McGinn CJ, et al: Radiosensitization by gemcitabine. Oncology 13:55-60, 1999 (suppl 5)